News - MedTech & Diagnostics
College of Pathologists strongly recommends to conserve lab swabs for urgent COVID-19 tests

Due to a limited supply, the Royal College of Pathologists of Australasia (RCPA) is calling for all clinicians, GPs and healthcare providers to conserve the utilisation of all lab swabs, by limiting any unnecessary or non-urgent testing, such as for chronic leg ulcers.
Dr Michael Dray, President of the Royal College of Pathologists of Australasia said, “It is essential that the use of all swabs is conserved to critical testing only. Currently, swabs should only be utilised for the testing of COVID-19 where they meet testing criteria, and for other urgent conditions.
“It is important to acknowledge that laboratories are working at high capacity during this period of increased demand, therefore, we seek the assistance of our healthcare colleagues to ensure that all tests are prioritised as much as possible.
Register FREE and join 20,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
“Pathologists and Scientists are playing a critical role during this pandemic, as they work around the clock to deliver high-quality testing within short timeframes, whilst testing for and diagnosing COVID-19. The RCPA continues to be dedicated to ensuring that patients receive only the highest levels of care and receive the highest standards of quality testing, in order to ensure optimal patient outcomes.”
The RCPA is the leading organisation representing pathologists in Australasia and will continue to support pathologists and improve the use of pathology testing to achieve better healthcare in the community.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More